Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Next Previous
Trial Profile

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Cancer metastases; Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IMmotion010
  • Sponsors Chugai Pharmaceutical; Roche

Most Recent Events

  • 22 May 2025 Accordig to City of Hope National Medical Center media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3 in Chicago and online.
  • 04 Jun 2024 Results of an exploratory biomarker analysis assessing circulating kidney injury molecule-1 biomarker presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 08 Sep 2023 The trial has been completed in Netherlands, Germany, Denmark, Belgium, Poland, France and Spain according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top